ENYO Pharma featured in Biomim’BOOK 2021

Published on 07/05/2021

ENYO Pharma is featured in the 2021 edition of Biomim’BOOK, the first book dedicated to actors and stakeholders in Biomimetism and Bio-inspiration.
To see the full book: https://www.flickr.com/photos/biomimexpo/sets/72157718879047022/
To see ENYO Pharma double page: BIOMIM_BOOK 2021_ENYO PHARMA

Read next in 'Latest news'

• La Phase 2
• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)